Alzheimer's disease (AD), the most common type of progressive dementia in the elderly, is characterized by neurofibrillary tangles, reactive astrocytosis, activation of microglial cells, and parenchymal deposits of beta-amyloid peptides (Abeta). The Abeta peptide (40-42 residues) is generated by the constitutive proteolytic processing of the amyloid precursor protein (APP). Several converging lines of evidence suggest that the deposition of the 42-residue form of Abeta is an early and critical event in the pathogenesis of Alzheimer's disease. Mutations in either APP, or presenilins 1 and 2 (PS), associated with familial AD (FAD) alter the cleavage of APP to favor production of the longer, more amyloidogenic, 42 residue amyloid beta peptide relative to the normally more abundant Abeta40. Together with this shift in the proportion of each Abeta species, transgenic mice co-expressing FADvariants of APP and PS1 develop Abeta deposits much earlier than mice expressing mutant APP alone. Hence, there is considerable genetic evidence to implicate amyloid deposition as one of the potential initiating insults in Alzheimer's disease. Indeed, most of the larger pharmaceutical companies and many smaller biotech enterprises are actively developing compounds that are designed to inhibit Abeta production and/or deposition. However, apart from some of the immunization studies, which we mechanistically do not understand, little is known about the capacity of mammalian brain to repair damage associated with amyloid deposition. Recently, using funds provided by a pilot project in the JHU Alzheimer's Disease Research Center, we have developed new strains of mice that express high levels of mutant APP under the transcriptional control of promoter elements that can be regulated by tetracycline. We now propose five Aims to further develop and characterize our new model and then to use these animals to ask fundamental questions regarding both the deposition of amyloid and the ability of the nervous system to repair damage caused by amyloid plaques. In a sixth Aim, we will use this new technology to create mice that express wild type and mutant tau in an effort to produce mice that model, in a regulate-able fashion, both of the major pathological aspects of Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS047225-03
Application #
7002173
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Sutherland, Margaret L
Project Start
2004-01-01
Project End
2006-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
3
Fiscal Year
2006
Total Cost
$369,209
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Xu, Guilian; Ran, Yong; Fromholt, Susan E et al. (2015) Murine A? over-production produces diffuse and compact Alzheimer-type amyloid deposits. Acta Neuropathol Commun 3:72
Savonenko, Alena V; Melnikova, Tatiana; Wang, Yuchuan et al. (2015) Cannabinoid CB2 Receptors in a Mouse Model of A? Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PLoS One 10:e0129618
Melnikova, Tatiana; Fromholt, Susan; Kim, HyunSu et al. (2013) Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci 33:3765-79
Njie, eMalick G; Kantorovich, Svetlana; Astary, Garrett W et al. (2012) A preclinical assessment of neural stem cells as delivery vehicles for anti-amyloid therapeutics. PLoS One 7:e34097
Njie, Emalick G; Boelen, Ellen; Stassen, Frank R et al. (2012) Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging 33:195.e1-12
Savonenko, Alena V; Melnikova, Tatiana; Hiatt, Andrew et al. (2012) Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology 37:261-77
Tucker, Stina M Fangmark; Borchelt, David R; Troncoso, Juan C (2008) Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol 67:30-40
Wang, Jiou; Xu, Guilian; Borchelt, David R (2006) Mapping superoxide dismutase 1 domains of non-native interaction: roles of intra- and intermolecular disulfide bonding in aggregation. J Neurochem 96:1277-88
Jankowsky, Joanna L; Slunt, Hilda H; Gonzales, Victoria et al. (2005) Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med 2:e355
Wang, Jiou; Xu, Guilian; Li, Hong et al. (2005) Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation. Hum Mol Genet 14:2335-47